Patents Examined by Layla Soroush
  • Patent number: 10653671
    Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 19, 2020
    Assignee: S.L.A. PHARMA, AG
    Inventors: David Nigel Armstrong, Justin Slagel
  • Patent number: 10640490
    Abstract: The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: May 5, 2020
    Assignee: Yuhan Corporation
    Inventors: Hyun-Joo Lee, Dong-Hoon Kim, Tae-Kyun Kim, Young-Ae Yoon, Jae-Young Sim, Myung-Hun Cha, Eun-Jung Jung, Kyoung-Kyu Ahn, Tai-Au Lee
  • Patent number: 10610469
    Abstract: Calcium phosphate (“CAP”) particles for use in cosmetic, nutraceutic or aesthetic medicine. The particles may be used as carriers for cosmetic, nutraceutic or a factors, as controlled release matrices for the material, and as fillers in cosmetic treatments. The particles may be applied topically or injected or by any other appropriate delivery method.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 7, 2020
    Inventor: Stephen J. D. Bell
  • Patent number: 10583130
    Abstract: The present disclosure relates to compositions and pharmaceutical formulations comprising at least one active pharmaceutical ingredient chosen from nitrocatechol derivatives of formula I as defined herein and salts, esters, hydrates, solvates and derivatives thereof and methods of making said compositions and pharmaceutical formulations.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 10, 2020
    Assignee: BIAL-PORTELA & CA, S.A.
    Inventors: Teofilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
  • Patent number: 10561674
    Abstract: The present invention discloses processes for the preparation of phospholipid-enriched dairy products as nutraceuticals for the formulation of functional foods, the processes include the steps of: combining a non-dairy-based PL-containing material, having phosphatidylserine (PS) and/or phosphatidic acid (PA) in the PL-containing material, wherein the PS and/or PA is derived in part from an enzymatically-processed lecithin as a PS-calcium and/or -magnesium salt and/or a PA-calcium and/or-magnesium salt via transphosphatidylation with phospholipase D in the presence of L-serine and a calcium and/or magnesium salt, with water and an oil component to form a paste; removing an excess amount of the water from the paste to form a PL-oil solution; and mixing the PL-oil solution with a dairy component, thereby obtaining a PL-enriched dairy product. Alternatively, the PL-oil solution has a weight-to-weight (w-w) concentration of at least about 0.01% of a residual amount of the water to the PL-containing material.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: February 18, 2020
    Assignee: Lipogen Ltd.
    Inventors: David Rutenberg, Ilan Perry
  • Patent number: 10493008
    Abstract: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: December 3, 2019
    Assignee: BRUDY TECHNOLOGY, S.L.
    Inventors: Joan Carles Domingo Pedrol, Jose Antonio Villegas Garcia
  • Patent number: 10455832
    Abstract: The present disclosure generally relates to the field of pest elimination including all life stages of bed bugs. The present disclosure includes compositions and methods of product application to target and kill all life stages of bed bugs.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: October 29, 2019
    Assignee: Ecolab USA Inc.
    Inventors: Joelle Francine Olson, Larry Mitchell Lark, Staci Jo Johnson, Erin Fransen Loosbrock, William Jeffery Pattison
  • Patent number: 10449254
    Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: October 22, 2019
    Assignees: The Regents of the University of California, Triad National Security, LLC, Arizona Board of Regents c/o Northern Arizona University
    Inventors: Michael Zakrewsky, Samir Mitragotri, David T. Fox, Andrew Koppisch, Rico Del Sesto, Katherine Lovejoy
  • Patent number: 10413555
    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 17, 2019
    Assignee: TROPHEA DEVELOPMENT AB
    Inventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
  • Patent number: 10399985
    Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 3, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden
  • Patent number: 10376500
    Abstract: The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: August 13, 2019
    Assignee: CELL THERAPY AND TECHNOLOGY S.A. DE C.V.
    Inventors: José Agustin Rogelio Magaña Castro, Laura Vázquez Cervantes, Juan Socorro Armendáriz Borunda
  • Patent number: 10357503
    Abstract: This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the manufacture of such a formulation for use in the method and to a method of preparing said formulation. The formulation of the present invention is a combination of active principals for use in the prevention of cardiovascular disease, notably ischaemic heart disease (including heart attacks) and stroke among the general adult population.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 23, 2019
    Inventors: Nicholas J Wald, Malcolm R Law
  • Patent number: 10351574
    Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 16, 2019
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10342769
    Abstract: The present invention provides pharmaceutical formulations of lyophilized carmustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized carmustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with carmustine, such as neoplastic diseases.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: July 9, 2019
    Assignee: Navinta III Inc
    Inventor: Mahendra R. Patel
  • Patent number: 10342797
    Abstract: Disclosed herein are methods and compositions to improve the solubility of therapeutic agents. In one embodiment, a method of improving solubility of a therapeutic agent includes mixing fullerene in a lipid solution to form a lipofullerene mixture, and mixing the therapeutic agent with the lipofullerene mixture.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 9, 2019
    Assignee: LivePet, LLC
    Inventors: Ian Mitchell, Daniel David Bensimon, Ayyappan Subbiah, Rajashekharam Malyala
  • Patent number: 10292956
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 21, 2019
    Assignee: Serbig Pharmaceutics Corp.
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Patent number: 10285997
    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: May 14, 2019
    Assignee: TROPHEA DEVELOPMENT AB
    Inventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
  • Patent number: 10265363
    Abstract: The present invention provides formulations that support an individual's body during routine vaccination and adaptive immune response. The individuals who can benefit front these formulations are infants, children and adults. The formulations comprise ingredients that can be administered prior to, concurrent with or subsequent to the vaccination. The formulations of the present invention preferably act by targeting enzymatic reactions an individual's various metabolic pathways, maintaining balance between oxidative stress and methylation, maintaining balance between Th1 and Th2 responses, or a combination thereof during vaccination and adaptive immune response.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: April 23, 2019
    Inventors: Sarah Morgan, Karl Holtzer
  • Patent number: 10238646
    Abstract: The present invention relates to methods for treating pruritus with anti-pruritic compositions.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: March 26, 2019
    Assignee: Trevi Therapeutics Inc.
    Inventor: Thomas Sciascia
  • Patent number: 10226043
    Abstract: A controlled release biocidal salt of a first component comprises a cation of a N?-(C1-C22) alkanoyl di-basic amino acid alkyl (C1-C22) ester cationic biocidal molecule and a second component comprising an anion of a monomeric anionic molecule having insignificant biocidal activity. The salt is characterized such that when the salt is exposed to an aqueous medium, the salt partially dissolves thereby releasing biocidal ions in an amount sufficient to exceed the MIC or MBC of a target bacteria being controlled, and further characterized as leaving a residual reservoir of undissolved salt capable of releasing more biocidal ions as the salt is consumed or otherwise removed from the environment encompassing the target bacteria. The preferred cationic biocidal molecule comprises N?-lauroyl-L-arginine ethyl ester (“LAE”).
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: March 12, 2019
    Assignee: NEVADA NATURALS INC.
    Inventors: Anthony J. Sawyer, Richard F. Stockel